Is GlobalFoundries On The Verge Of A Breakout?
GLOBALFOUNDRIES Inc. (NASDAQ:GFS) is as a semiconductor foundry whose chips…
Sell
39
RXST Quote, Financials, Valuation and Earnings
Last price:
$16.03
Seasonality move
:
9.21%
Day range:
$15.84 - $16.74
52-week range:
$12.53 - $64.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.46x
P/B ratio:
2.42x
Volume:
970.4K
Avg. volume:
1.2M
1-year change:
-73.47%
Market cap:
$675.4M
Revenue:
$139.9M
EPS (TTM):
-$0.67
Analysts' Opinion
-
Consensus RatingRxSight has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $21.18, RxSight has an estimated upside of 27.45% from its current price of $16.62.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 3.73% downside risk from its current price of $16.62.
Fair Value
-
According to the consensus of 7 analysts, RxSight has 27.45% upside to fair value with a price target of $21.18 per share.
RXST vs. S&P 500
-
Over the past 5 trading days, RxSight has overperformed the S&P 500 by 25.41% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
RxSight does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
RxSight has grown year-over-year revenues for 0 quarters straight. In the most recent quarter RxSight reported revenues of $37.9M.
Earnings Growth
-
RxSight has grown year-over-year earnings for 0 quarters straight. In the most recent quarter RxSight reported earnings per share of -$0.20.
Enterprise value:
446M
EV / Invested capital:
1.60x
Price / LTM sales:
4.46x
EV / EBIT:
--
EV / Revenue:
3.01x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-21.74x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$106.6M
Return On Assets:
-9.28%
Net Income Margin (TTM):
-17.9%
Return On Equity:
-10.39%
Return On Invested Capital:
-10.39%
Operating Margin:
-28.17%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $57.6M | $101.1M | $148.3M | $29.5M | $37.9M | |
| Gross Profit | $27.9M | $64.1M | $106.6M | $20.7M | $28.3M | |
| Operating Income | -$59.8M | -$47.7M | -$36.9M | -$10.7M | -$10.7M | |
| EBITDA | -$53M | -$38.3M | -$23.2M | -$7.9M | -$7.4M | |
| Diluted EPS | -$2.20 | -$1.25 | -$0.67 | -$0.25 | -$0.20 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $77.8M | $161.1M | $187.7M | $168.6M | $288.4M | |
| Total Assets | $96.3M | $177.1M | $202.5M | $183.2M | $313M | |
| Current Liabilities | $6.9M | $10.7M | $14.9M | $18.3M | $22.7M | |
| Total Liabilities | $398.2M | $53.9M | $57.5M | $19.2M | $33.7M | |
| Total Equity | -$301.9M | $123.2M | $145M | $163.9M | $279.3M | |
| Total Debt | $29.5M | $39.9M | $40.3M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$61.6M | -$33.1M | -$16.5M | -$9.3M | -$8.8M | |
| Cash From Investing | -$23.3M | $50.5M | -$102.7M | $24.3M | $20.9M | |
| Cash From Financing | $71.7M | $4.2M | $114.6M | $8M | -$735K | |
| Free Cash Flow | -$64.4M | -$39.2M | -$20.5M | -$11.3M | -$9.4M | |
RXST
Sector
Market Cap
$675.4M
$34.2M
Price % of 52-Week High
25.77%
43.73%
Dividend Yield
0%
0%
Shareholder Yield
-11.66%
-0.66%
1-Year Price Total Return
-73.47%
-41.71%
Beta (5-Year)
--
0.657
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$14.21
200-day SMA
Sell
Level
$36.86
Bollinger Bands (100)
Sell
Level
17.18 - 32.92
Chaikin Money Flow
Sell
Level
-2.5M
20-day SMA
Buy
Level
$14.50
Relative Strength Index (RSI14)
Buy
Level
55.67
ADX Line
Buy
Level
29.13
Williams %R
Sell
Level
-2.8504
50-day SMA
Sell
Level
$18.35
MACD (12, 26)
Sell
Level
-0.82
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
10.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (20.774)
Buy
CA Score
(Annual)
Level (1.0115)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.5487)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Stock Forecast FAQ
In the current month, RXST has received 4 Buy ratings 3 Hold ratings, and 0 Sell ratings. The RXST average analyst price target in the past 3 months is $21.18.
-
Where Will RxSight Stock Be In 1 Year?
According to analysts, the consensus estimate is that RxSight share price will rise to $21.18 per share over the next 12 months.
-
What Do Analysts Say About RxSight?
Analysts are divided on their view about RxSight share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that RxSight is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is RxSight's Price Target?
The price target for RxSight over the next 1-year time period is forecast to be $21.18 according to 7 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is RXST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for RxSight is a Buy. 4 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RXST?
You can purchase shares of RxSight via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase RxSight shares.
-
What Is The RxSight Share Price Today?
RxSight was last trading at $16.03 per share. This represents the most recent stock quote for RxSight. Yesterday, RxSight closed at $16.62 per share.
-
How To Buy RxSight Stock Online?
In order to purchase RxSight stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Dick’s Sporting Goods Buying Foot Locker Smart?
Last week, Dick’s Sporting Goods (NYSE:DKS) announced that it would…
Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Alerts
Buy
55
RGC alert for May 21
Regencell Bioscience Holdings [RGC] is down 3.24% over the past day.
Buy
64
AKRO alert for May 21
Akero Therapeutics [AKRO] is up 1.56% over the past day.
Buy
76
AGYS alert for May 21
Agilysys [AGYS] is down 1.32% over the past day.
